miR-27a-5p Mimic for C. difficile Bowel Inflammation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for Clostridium difficile-induced bowel inflammation are inadequate in modulating the inflammatory response, leading to severe clinical manifestations and high healthcare costs, with existing therapies failing to effectively inhibit pathways like NF-κB.
Innovation Solution
A pharmaceutical composition containing a miR-27a-5p mimic, which can be administered intravenously or orally, is used to inhibit the NF-κB pathway by modulating the inflammatory response, thereby reducing intestinal lesions and clinical symptoms of Clostridium difficile infection.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional antibiotic treatments are used for Clostridium difficile infection, then the infection can be treated, but the inflammatory response is not effectively modulated and severe clinical manifestations occur
Solution Approach 1:
The patent introduces miR-27a-5p as an intermediary molecular mediator that bridges the gap between C. difficile infection and intestinal inflammation. This microRNA acts as a therapeutic agent that specifically modulates the inflammatory response by targeting NF-κB pathway components, thereby reducing harmful inflammatory effects while maintaining treatment effectiveness against the bacterial infection
Solution Approach 2:
The patent applies parameter changes by targeting and modulating specific molecular parameters in the NF-κB signaling pathway. By altering the expression or activity levels of key pathway components through miR-27a-5p, the patent achieves effective control of intestinal inflammation while preserving the body's ability to fight the infection
2Reliability
If existing therapies are used to treat CDI, then the infection is addressed, but the NF-κB pathway remains active causing severe clinical manifestations
Solution Approach 1:
The patent extracts and specifically targets the harmful NF-κB pathway activation from the overall immune response. By using miR-27a-5p to selectively inhibit NF-κB signaling components, the patent separates and removes the harmful inflammatory effect while preserving the beneficial infection-fighting immune response
Solution Approach 2:
The patent converts the harmful NF-κB pathway activation into a beneficial controlled response. Through miR-27a-5p therapy, the pathway is redirected to function appropriately - maintaining necessary immune activation for infection control while eliminating excessive inflammation that causes severe clinical manifestations
3Reliability
If patient isolation and extended hospital stays are implemented, then CDI management is ensured, but healthcare costs increase significantly
Solution Approach 1:
The patent enables the patient's own immune system to effectively manage the infection through miR-27a-5p therapy. By providing the therapeutic microRNA, patients can clear the infection and control inflammation independently, reducing the need for extensive hospital isolation and prolonged medical intervention, thereby lowering healthcare costs while maintaining care quality
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The miR-27a-5p mimic significantly reduces intestinal inflammation and clinical manifestations of CDI by inhibiting the NF-κB pathway, providing a therapeutic approach to prevent or decrease intestinal lesions in infected subjects.
Implementation Method 1
microRNAs (miRNAs), non-coding RNA sequences of 21 to 24 nucleotides, responsible for the post-transcriptional regulation of genes by their specific action on m RNAs
Implementation Method 2
the NF-κB pathway seems to be the predominant pathway... toxins acted in cooperation with C. difficile flagella to induce an inflammatory response
Data Source
AI summary
The present inventors have identified an miRNA capable of greatly modulating the inflammatory response induced by Clostridium difficile. They thus propose incorporating this miRNA into a pharmaceutical composition for preventing or reducing the harmful effects of this infection on the bowels of infected patients. This microRNA is miR-27a-5p. Advantageously, this miRNA can be linked to a matrix, incorporated into particles, or conveyed by a vector. It can be administered to infected subjects for therapeutic purposes.